Skip to content

Mind-altering substances are (still) falling short in clinical trials

0.4558
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Mind-altering substances are (still) falling short in clinical trials Placebo and “knowcebo” effects are a problem. But they can also help people feel better. This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are...
The strongest version of this narrative acknowledges the genuine scientific and cultural excitement around psychedelics while highlighting the methodological flaws that have inflated their perceived efficacy. The studies cited demonstrate a critical gap between hype and evidence, revealing how the "knowcebo effect" and unblinded trial designs can distort results. This isn’t just a critique of psychedelics but a broader commentary on how placebo effects—both positive and negative—shape medical re...